Research
About
Back
Funding Approach
The Guthy-Jackson Charitable Foundation (GJCF) is committed to enhancing the scientific and clinical knowledge base by supporting innovative research to accelerate solutions for NMOSD. Funding priorities are those that advance understanding of the pathophysiology and immunology of this disease in a manner that enables translation to clinical benefit and betterment of the NMOSD patient community. Researchers funded by GJCF are required to share research findings promptly and participate in collaborative initiatives via the GJCF International Clinical Consortium for NMOSD and other GJCF programs. To this end, regular progress reports and attendance at the annual GJCF International NMOSD conference to share insights and strategies for new ways to study and ultimately solve NMOSD are terms of research funding agreements.
Types of Grants Funded
The GJCF prioritizes leading-edge research focused on state-of-the art approaches to prevent, understand, safely and effectively treat, and ultimately cure NMOSD.
- Eureka Grant. A Eureka grant aims to uncover a fundamentally new concept in NMOSD. A Eureka grant may be hypothesis generating, proof-of-concept establishing, pilot study, or equivalent. Eureka grants are sharply focused on a priority unmet need or question, and may be high risk.
Maximum Funding: Up to $50,000 U.S.
Maximum Duration: Up to 1 year
Funding Requirements
All GJCF funded research grants require: a) a clear pathway for NMOSD patient benefit; b) specific milestones to be accomplished in each period of the project; c) a data sharing plan; and d) a specific plan to obtain follow-on research funding beyond the GJCF (e.g. NIH or equivalent agency or commercial funding). Ongoing funding of all grant types is dependent on documented progress/milestones in the prior review period, typically every quarter or 6 months in frequency.
Funding Intervals
The GJCF funds projects using a tranche model, with ongoing funding contingent on evidence-based achievement of milestones specified in the prior project period.
Indirect Cost Rate
In keeping with appropriate practices of small, non-profit, research-based foundations, the GJCF considers up to a 10% indirect cost rate when research is exclusively conducted at academic or non-profit institutions.
Cost Sharing
The GJCF encourages applications in which cost sharing with other sources is integral. Sources for cost sharing may include the NIH or equivalent agencies, other disease-focused organizations (e.g. NMSS), commercial interests and other appropriate funding entities.
Funding Eligibility
The GJCF is a non-profit foundation acting independently of any medical, academic or government institution. All consideration and decisions regarding funding eligibility are at the sole discretion of the foundation.
Application Process
Letters of Intent (LOI) regarding interest in funding consideration are welcomed, with decisions based solely on the foundation discretion. Focused on solving NMOSD, an LOI of up to 2 pages should succinctly state the unmet need or unanswered question, detail innovative concepts, methods or reagents, identify a PI and research team members, define research milestones and timeline, and specify a projected budget. Submissions are subject to review by the GJCF scientific advisory team and eligibility requirements (as above). GJCF representatives may request additional information regarding LOI content. Formal research applications are allowed upon approval by GJCF. Send LOI to info@guthyjacksonfoundation.org.
Funded Researchers
Back
-
Vijay Kuchroo, DVM, PhDBack
Vijay Kuchroo, DVM, PhDResearch TopicGeneration of a humanized animal model for neuromyelitis optica (NMO) to study the interaction between aquaporin-4 (AQP4)-specific T and B cellsTypeScientificStatusCurrentTimeline2015 - 2018Researcher(s)Vijay Kuchroo, DVM, PhDHarvard Brigham and Women's HospitalResearch TopicInteraction between myelin specific T and B cells in inducing Neuromyelitis OpticaTypeScientificStatusCompleteTimeline2010 - 2013Researcher(s)Vijay Kuchroo, DVM, PhDHarvard Brigham and Women's Hospital -
Vanda Lennon, MD, PhDBack Vanda Lennon, MD, PhDResearch TopicDevelopment and Validation of Aquaporin Autoimmunity ModelsTypeScientificStatusCompleteTimeline2008 - 2011Researcher(s)Vanda Lennon, MD, PhDMayo Clinic
-
Thomas Tedder, PhDBack Thomas Tedder, PhDResearch TopicIdentifying the microbial and self antigenomes of NMO/NMOSDTypeScientificStatusCurrentTimeline2014 - 2016Researcher(s)Thomas Tedder, PhDDuke University
-
Tanuja Chitnis, MDBack
Tanuja Chitnis, MDResearch TopicClinical and MRI features of NMO spectrum disorders in childrenTypeClinicalStatusCurrentTimeline2012 - 2015Researcher(s)Tanuja Chitnis, MDMassachusetts General HospitalResearch TopicNMO placental repository and immunohistological evaluationTypeScientificStatusCurrentTimeline2017 - 2018Researcher(s)Tanuja Chitnis, MDMassachusetts General Hospital -
Stan Nelson, MDBack Stan Nelson, MDResearch TopicGenome-wide association study of Neuromyelitis OpticaTypeScientificStatusCompleteTimeline2012 - 2012Researcher(s)Stan Nelson, MDUniversity of California, Los Angeles
-
Sean Pittock, MDBack Sean Pittock, MDResearch Topic"Bench to Bedside" Investigation of Aquaporin-4 (AQP4) Autoimmunity: Epidemiology and TranslationTypeClinicalStatusCurrentTimeline2008 - 2015Researcher(s)Sean Pittock, MDMayo Clinic
-
Scott Zamvil, MD, PhDBack Scott Zamvil, MD, PhDResearch TopicAquaporin-4 (AQP4)-specific T cells in CNSTypeScientificStatusCompleteTimeline2012 - 2015Researcher(s)Scott Zamvil, MD, PhDUniversity of California, San FranciscoResearch TopicGastrointestinal microbiome in neuromyelitis opticaTypeClinicalStatusCompleteTimeline2012 - 2015Researcher(s)Scott Zamvil, MD, PhDUniversity of California, San FranciscoResearch TopicT cell recognition of aquaporin-4 in neuromyelitis opticaTypeScientificStatusCompleteTimeline2008 - 2012Researcher(s)Scott Zamvil, MD, PhDUniversity of California, San Francisco
-
Roberto Baccala, PhDBack Roberto Baccala, PhDResearch TopicMolecular studies of Neuromyelitis Optica in mouse models of aquaporin-4 autoimmunityTypeScientificStatusCompleteTimeline2009 - 2011Researcher(s)Roberto Baccala, PhDThe Scripps Research Institute
-
Robert Stroud, PhDBack Robert Stroud, PhDResearch TopicProduction of human aquaporin 4 (hAQP4)TypeScientificStatusCurrentTimeline2017 - 2019Researcher(s)Robert Stroud, PhDUniversity of California, San Francisco
-
Richard Ransohoff, MDBack Richard Ransohoff, MDResearch TopicEffects of NMO-IgG at the blood brain barrier in vitroTypeScientificStatusCompleteTimeline2014 - 2014Researcher(s)Richard Ransohoff, MDCleveland ClinicResearch TopicEffects of NMO-IgG at the blood brain barrier in vitro under flow conditionsTypeScientificStatusCompleteTimeline2012 - 2014Researcher(s)Richard Ransohoff, MDCleveland Clinic
-
Michael Levy, MD, PhDBack Michael Levy, MD, PhDResearch TopicAnti-VEGF therapy for Neuromyelitis OpticaTypeClinicalStatusCompleteTimeline2013 - 2014Researcher(s)Michael Levy, MD, PhDJohns HopkinsGareth John, PhDMount SinaiResearch TopicAquaporin-4 variants and astrocyte diversity in the immunopathogenesis of NMOTypeScientificStatusCompleteTimeline2009 - 2012Researcher(s)Michael Levy, MD, PhDJohns HopkinsResearch TopicNeuromyelitis Optica Clinical ConsortiumTypeClinicalStatusCompleteTimeline2010 - 2011Researcher(s)Michael Levy, MD, PhDJohns HopkinsDean Wingerchuk, MDMayo ClinicBenjamin Greenberg, MDUT Southwestern
-
May Han, MDBack May Han, MDResearch TopicBlood biomarkers to predict disease activity in Neuromyelitis Optica and pathogenesisTypeScientificStatusCompleteTimeline2012 - 2014Researcher(s)May Han, MDStanford
-
Marios Papadopoulos, MDBack Marios Papadopoulos, MDResearch TopicPathogenesis of Neuromyelitis OpticaTypeScientificStatusCompleteTimeline2012 - 2014Researcher(s)Marios Papadopoulos, MDSt. George's, University of LondonResearch TopicPathogenesis of seropositive and seronegative NMOTypeScientificStatusCurrentTimeline2014 - 2016Researcher(s)Marios Papadopoulos, MDSt. George's, University of London
-
Lawrence Steinman, MDBack Lawrence Steinman, MDResearch TopicAntigen specific tolerance to AQP4: TolVax-AQP4TypeScientificStatusCurrentTimeline2015 - 2017Researcher(s)Lawrence Steinman, MDStanfordResearch TopicPotential biomarkers for disease activity in Neuromyelitis OpticaTypeScientificStatusCompleteTimeline2012 - 2014Researcher(s)Lawrence Steinman, MDStanfordResearch TopicProteomic Studies Leading to Development of Tolerizing Therapy in NMOTypeScientificStatusCompleteTimeline2008 - 2012Researcher(s)Lawrence Steinman, MDStanford
-
Lawrence Cook, PhDBack Lawrence Cook, PhDResearch TopicMaintain a Functional Infrastructure for an NMO Patient RegistryTypeScientificStatusCurrentTimeline2018 - 2019Researcher(s)Lawrence Cook, PhDUniversity of UtahResearch TopicNMO Data Coordinating CenterTypeClinicalStatusCurrentTimeline2013 - 2016Researcher(s)Lawrence Cook, PhDUniversity of UtahJohn Rose, MDUniversity of UtahResearch TopicXNAT Imaging RepositoryTypeScientificStatusCurrentTimeline2015 - 2018Researcher(s)Lawrence Cook, PhDUniversity of Utah
-
Kevin O’Connor, PhDBack Kevin O’Connor, PhDResearch TopicB cell tolerance defects in NMOTypeScientificStatusCurrentTimeline2015 - 2016Researcher(s)Kevin O’Connor, PhDYale UniversityResearch TopicExploring immune response to vaccine antigens in NMOSD and autoimmunityTypeScientificStatusCurrentTimeline2017 - 2019Researcher(s)Kevin O’Connor, PhDYale University
-
John Rose, MDBack John Rose, MDResearch TopicNMO Data Coordinating CenterTypeClinicalStatusCurrentTimeline2013 - 2016Researcher(s)Lawrence Cook, PhDUniversity of UtahJohn Rose, MDUniversity of Utah
-
Jeffrey Bennett, MD, PhDBack Jeffrey Bennett, MD, PhDResearch TopicAQP4 autoantibodies and disease pathogenesis in Neuromyelitis OpticaTypeScientificStatusCompleteTimeline2012 - 2014Researcher(s)Jeffrey Bennett, MD, PhDUniversity of Colorado, DenverResearch TopicAQP4-specific immunotherapy in Neuromyelitis OpticaTypeScientificStatusCompleteTimeline2010 - 2012Researcher(s)Jeffrey Bennett, MD, PhDUniversity of Colorado, DenverResearch TopicMonitoring humoral immunity and complement injury in Neuromyelitis OpticaTypeScientificStatusCurrentTimeline2014 - 2016Researcher(s)Jeffrey Bennett, MD, PhDUniversity of Colorado, DenverResearch TopicProduction of AQP4-specific rAbTypeScientificStatusCurrentTimeline2017 - 2018Researcher(s)Jeffrey Bennett, MD, PhDUniversity of Colorado, DenverResearch TopicSecond-generation aquaporumabs and NMO superantibodies for NMO research and therapyTypeScientificStatusCompleteTimeline2012 - 2014Researcher(s)Jeffrey Bennett, MD, PhDUniversity of Colorado, DenverAlan Verkman, MD, PhDUniversity of California, San Francisco
-
Jacqueline Palace, MDBack Jacqueline Palace, MDResearch TopicDeveloping Magnetic Resonance Spectroscopy and High Field Spinal Cord MRI as a Tool for Studying the Pathology and Symptoms of Neuromyelitis OpticaTypeClinicalStatusCompleteTimeline2013 - 2014Researcher(s)Jacqueline Palace, MDOxford UniversityResearch TopicThe international Neuromyelitis Optica genetics consortium: a genome-wide approach for studying disease etiologyTypeClinicalStatusCurrentTimeline2014 - 2016Researcher(s)Jacqueline Palace, MDOxford University
-
Ilya Kister, MDBack Ilya Kister, MDResearch TopicCan Neuromyelitis Optica be differentiated from 'conventional' Multiple Sclerosis with ultra-high field brain imaging?TypeClinicalStatusCompleteTimeline2012 - 2013Researcher(s)Ilya Kister, MDNew York UniversityResearch TopicCerebral ultra-high field MR imaging in Neuromyelitis Optica: US-German longitudinal studyTypeClinicalStatusCurrentTimeline2013 - 2015Researcher(s)Ilya Kister, MDNew York University
-
Ilana Katz Sand, MDBack Ilana Katz Sand, MDResearch TopicAn open-label add-on trial of cetirizine for neuromyelitis opticaTypeClinicalStatusCurrentTimeline2013 - 2015Researcher(s)Ilana Katz Sand, MDMount Sinai
-
Hollie SchmidtBack Hollie SchmidtResearch TopicStorage, maintenance, and distribution of repository samplesTypeScientificStatusCurrentTimeline2017 - 2018Researcher(s)Hollie SchmidtAccelerated Cure Project
-
Gareth John, PhDBack Gareth John, PhDResearch TopicAnti-VEGF therapy for Neuromyelitis OpticaTypeClinicalStatusCompleteTimeline2013 - 2014Researcher(s)Michael Levy, MD, PhDJohns HopkinsGareth John, PhDMount Sinai
-
Friedemann Paul, MDBack Friedemann Paul, MDResearch TopicThe Collaborative Retrospective Study on retinal OCT in Neuromyelitis Optica (CROCTINO)TypeScientificStatusCurrentTimeline2016 - 2017Researcher(s)Friedemann Paul, MDCharité UniversityResearch TopicThe Parallel Study on MRI in Neuromyelitis Optica (PAMRINO)TypeScientificStatusCurrentTimeline2016 - 2017Researcher(s)Friedemann Paul, MDCharité University
-
Eric Klawiter, MDBack Eric Klawiter, MDResearch TopicThe effect of pregnancy on Neuromyelitis OpticaTypeClinicalStatusCompleteTimeline2011 - 2014Researcher(s)Eric Klawiter, MDMassachusetts General Hospital
-
Dean Wingerchuk, MDBack Dean Wingerchuk, MDResearch TopicInternational Panel on Neuromyelitis Optica Diagnosis (IPND)TypeClinicalStatusCompleteTimeline2012 - 2014Researcher(s)Dean Wingerchuk, MDMayo ClinicBrian Weinshenker, MDMayo ClinicResearch TopicNeuromyelitis Optica Clinical ConsortiumTypeClinicalStatusCompleteTimeline2010 - 2011Researcher(s)Michael Levy, MD, PhDJohns HopkinsDean Wingerchuk, MDMayo ClinicBenjamin Greenberg, MDUT Southwestern
-
Claudia Lucchinetti, MDBack Claudia Lucchinetti, MDResearch TopicSynergistic interactions between astrocytes, eosinophils and AQP4-IgG in NMOTypeScientificStatusCompleteTimeline2010 - 2014Researcher(s)Claudia Lucchinetti, MDMayo Clinic
-
Brian Weinshenker, MDBack Brian Weinshenker, MDResearch TopicGenetics of Neuromyelitis Optica and Molecular Basis of SusceptibilityTypeScientificStatusCompleteTimeline2008 - 2012Researcher(s)Brian Weinshenker, MDMayo ClinicResearch TopicInternational Panel on Neuromyelitis Optica Diagnosis (IPND)TypeClinicalStatusCompleteTimeline2012 - 2014Researcher(s)Dean Wingerchuk, MDMayo ClinicBrian Weinshenker, MDMayo Clinic
-
Benjamin Greenberg, MDBack Benjamin Greenberg, MDResearch TopicNeuromyelitis Optica Clinical ConsortiumTypeClinicalStatusCompleteTimeline2010 - 2011Researcher(s)Michael Levy, MD, PhDJohns HopkinsDean Wingerchuk, MDMayo ClinicBenjamin Greenberg, MDUT SouthwesternResearch TopicNMO Clinical StudyTypeClinicalStatusCurrentTimeline2015 - 2017Researcher(s)Benjamin Greenberg, MDUT Southwestern
-
Anthony Traboulsee, MDBack Anthony Traboulsee, MD
-
Alan Verkman, MD, PhDBack Alan Verkman, MD, PhDResearch TopicCD59 Knock-out RatTypeScientificStatusCompleteTimeline2013 - 2015Researcher(s)Alan Verkman, MD, PhDUniversity of California, San FranciscoResearch TopicGeneration, characterization and application of AQP4 knockout ratTypeScientificStatusCurrentTimeline2015 - 2016Researcher(s)Alan Verkman, MD, PhDUniversity of California, San FranciscoResearch TopicModels to study NMO disease mechanisms and new therapiesTypeScientificStatusCurrentTimeline2014 - 2016Researcher(s)Alan Verkman, MD, PhDUniversity of California, San FranciscoResearch TopicNMO: New therapies, models and pathogenesis mechanismsTypeScientificStatusCompleteTimeline2012 - 2014Researcher(s)Alan Verkman, MD, PhDUniversity of California, San FranciscoResearch TopicNovel NMO therapeutics: development and animal efficacy studiesTypeScientificStatusCurrentTimeline2016 - 2018Researcher(s)Alan Verkman, MD, PhDUniversity of California, San FranciscoResearch TopicPharmacological upregulation of CD59 in NMOTypeScientificStatusCompleteTimeline2017 - 2018Researcher(s)Alan Verkman, MD, PhDUniversity of California, San FranciscoResearch TopicQuantitative analysis of AQP4 binding by NMO patient seraTypeScientificStatusCompleteTimeline2010 - 2011Researcher(s)Alan Verkman, MD, PhDUniversity of California, San FranciscoResearch TopicRole of AQP4 autoantibody in Neuromyelitis OpticaTypeScientificStatusCompleteTimeline2009 - 2012Researcher(s)Alan Verkman, MD, PhDUniversity of California, San FranciscoResearch TopicSecond generation rat modelsTypeScientificStatusCompleteTimeline2013 - 2014Researcher(s)Alan Verkman, MD, PhDUniversity of California, San FranciscoResearch TopicSecond-generation aquaporumabs and NMO superantibodies for NMO research and therapyTypeScientificStatusCompleteTimeline2012 - 2014Researcher(s)Jeffrey Bennett, MD, PhDUniversity of Colorado, DenverAlan Verkman, MD, PhDUniversity of California, San FranciscoResearch TopicSmall-molecule blocker therapy for NMOTypeScientificStatusCompleteTimeline2010 - 2011Researcher(s)Alan Verkman, MD, PhDUniversity of California, San Francisco
Institutions
Back
-
Accelerated Cure ProjectBackResearch TopicStorage, maintenance, and distribution of repository samplesTypeScientificStatusCurrentTimeline2017 - 2018Researcher(s)Hollie SchmidtAccelerated Cure Project
-
Charité UniversityBackResearch TopicThe Parallel Study on MRI in Neuromyelitis Optica (PAMRINO)TypeScientificStatusCurrentTimeline2016 - 2017Researcher(s)Friedemann Paul, MDCharité UniversityResearch TopicXNAT Imaging RepositoryTypeScientificStatusCurrentTimeline2015 - 2018Researcher(s)Lawrence Cook, PhDUniversity of Utah
-
Cleveland ClinicBackResearch TopicEffects of NMO-IgG at the blood brain barrier in vitroTypeScientificStatusCompleteTimeline2014 - 2014Researcher(s)Richard Ransohoff, MDCleveland ClinicResearch TopicEffects of NMO-IgG at the blood brain barrier in vitro under flow conditionsTypeScientificStatusCompleteTimeline2012 - 2014Researcher(s)Richard Ransohoff, MDCleveland Clinic
-
Duke UniversityBackResearch TopicIdentifying the microbial and self antigenomes of NMO/NMOSDTypeScientificStatusCurrentTimeline2014 - 2016Researcher(s)Thomas Tedder, PhDDuke University
-
Harvard Brigham and Women's HospitalBackResearch TopicGeneration of a humanized animal model for neuromyelitis optica (NMO) to study the interaction between aquaporin-4 (AQP4)-specific T and B cellsTypeScientificStatusCurrentTimeline2015 - 2018Researcher(s)Vijay Kuchroo, DVM, PhDHarvard Brigham and Women's HospitalResearch TopicInteraction between myelin specific T and B cells in inducing Neuromyelitis OpticaTypeScientificStatusCompleteTimeline2010 - 2013Researcher(s)Vijay Kuchroo, DVM, PhDHarvard Brigham and Women's Hospital
-
Johns HopkinsBackResearch TopicAnti-VEGF therapy for Neuromyelitis OpticaTypeClinicalStatusCompleteTimeline2013 - 2014Researcher(s)Michael Levy, MD, PhDJohns HopkinsGareth John, PhDMount SinaiResearch TopicAquaporin-4 variants and astrocyte diversity in the immunopathogenesis of NMOTypeScientificStatusCompleteTimeline2009 - 2012Researcher(s)Michael Levy, MD, PhDJohns HopkinsResearch TopicNeuromyelitis Optica Clinical ConsortiumTypeClinicalStatusCompleteTimeline2010 - 2011Researcher(s)Michael Levy, MD, PhDJohns HopkinsDean Wingerchuk, MDMayo ClinicBenjamin Greenberg, MDUT Southwestern
-
Massachusetts General HospitalBackResearch TopicClinical and MRI features of NMO spectrum disorders in childrenTypeClinicalStatusCurrentTimeline2012 - 2015Researcher(s)Tanuja Chitnis, MDMassachusetts General HospitalResearch TopicThe effect of pregnancy on Neuromyelitis OpticaTypeClinicalStatusCompleteTimeline2011 - 2014Researcher(s)Eric Klawiter, MDMassachusetts General Hospital
-
Mayo ClinicBackResearch Topic"Bench to Bedside" Investigation of Aquaporin-4 (AQP4) Autoimmunity: Epidemiology and TranslationTypeClinicalStatusCurrentTimeline2008 - 2015Researcher(s)Sean Pittock, MDMayo ClinicResearch TopicDevelopment and Validation of Aquaporin Autoimmunity ModelsTypeScientificStatusCompleteTimeline2008 - 2011Researcher(s)Vanda Lennon, MD, PhDMayo ClinicResearch TopicGenetics of Neuromyelitis Optica and Molecular Basis of SusceptibilityTypeScientificStatusCompleteTimeline2008 - 2012Researcher(s)Brian Weinshenker, MDMayo ClinicResearch TopicInternational Panel on Neuromyelitis Optica Diagnosis (IPND)TypeClinicalStatusCompleteTimeline2012 - 2014Researcher(s)Dean Wingerchuk, MDMayo ClinicBrian Weinshenker, MDMayo ClinicResearch TopicNeuromyelitis Optica Clinical ConsortiumTypeClinicalStatusCompleteTimeline2010 - 2011Researcher(s)Michael Levy, MD, PhDJohns HopkinsDean Wingerchuk, MDMayo ClinicBenjamin Greenberg, MDUT SouthwesternResearch TopicSynergistic interactions between astrocytes, eosinophils and AQP4-IgG in NMOTypeScientificStatusCompleteTimeline2010 - 2014Researcher(s)Claudia Lucchinetti, MDMayo Clinic
-
Mount SinaiBackResearch TopicAn open-label add-on trial of cetirizine for neuromyelitis opticaTypeClinicalStatusCurrentTimeline2013 - 2015Researcher(s)Ilana Katz Sand, MDMount SinaiResearch TopicAnti-VEGF therapy for Neuromyelitis OpticaTypeClinicalStatusCompleteTimeline2013 - 2014Researcher(s)Michael Levy, MD, PhDJohns HopkinsGareth John, PhDMount Sinai
-
New York UniversityBackResearch TopicCan Neuromyelitis Optica be differentiated from 'conventional' Multiple Sclerosis with ultra-high field brain imaging?TypeClinicalStatusCompleteTimeline2012 - 2013Researcher(s)Ilya Kister, MDNew York UniversityResearch TopicCerebral ultra-high field MR imaging in Neuromyelitis Optica: US-German longitudinal studyTypeClinicalStatusCurrentTimeline2013 - 2015Researcher(s)Ilya Kister, MDNew York University
-
Oxford UniversityBackResearch TopicDeveloping Magnetic Resonance Spectroscopy and High Field Spinal Cord MRI as a Tool for Studying the Pathology and Symptoms of Neuromyelitis OpticaTypeClinicalStatusCompleteTimeline2013 - 2014Researcher(s)Jacqueline Palace, MDOxford UniversityResearch TopicThe international Neuromyelitis Optica genetics consortium: a genome-wide approach for studying disease etiologyTypeClinicalStatusCurrentTimeline2014 - 2016Researcher(s)Jacqueline Palace, MDOxford University
-
St. George's, University of LondonBackResearch TopicPathogenesis of Neuromyelitis OpticaTypeScientificStatusCompleteTimeline2012 - 2014Researcher(s)Marios Papadopoulos, MDSt. George's, University of LondonResearch TopicPathogenesis of seropositive and seronegative NMOTypeScientificStatusCurrentTimeline2014 - 2016Researcher(s)Marios Papadopoulos, MDSt. George's, University of London
-
StanfordBackResearch TopicAntigen specific tolerance to AQP4: TolVax-AQP4TypeScientificStatusCurrentTimeline2015 - 2017Researcher(s)Lawrence Steinman, MDStanfordResearch TopicBlood biomarkers to predict disease activity in Neuromyelitis Optica and pathogenesisTypeScientificStatusCompleteTimeline2012 - 2014Researcher(s)May Han, MDStanfordResearch TopicPotential biomarkers for disease activity in Neuromyelitis OpticaTypeScientificStatusCompleteTimeline2012 - 2014Researcher(s)Lawrence Steinman, MDStanfordResearch TopicProteomic Studies Leading to Development of Tolerizing Therapy in NMOTypeScientificStatusCompleteTimeline2008 - 2012Researcher(s)Lawrence Steinman, MDStanford
-
The Scripps Research InstituteBackResearch TopicMolecular studies of Neuromyelitis Optica in mouse models of aquaporin-4 autoimmunityTypeScientificStatusCompleteTimeline2009 - 2011Researcher(s)Roberto Baccala, PhDThe Scripps Research Institute
-
University of California, Los AngelesBackResearch TopicGenome-wide association study of Neuromyelitis OpticaTypeScientificStatusCompleteTimeline2012 - 2012Researcher(s)Stan Nelson, MDUniversity of California, Los Angeles
-
University of California, San FranciscoBackResearch TopicAquaporin-4 (AQP4)-specific T cells in CNSTypeScientificStatusCompleteTimeline2012 - 2015Researcher(s)Scott Zamvil, MD, PhDUniversity of California, San FranciscoResearch TopicCD59 Knock-out RatTypeScientificStatusCompleteTimeline2013 - 2015Researcher(s)Alan Verkman, MD, PhDUniversity of California, San FranciscoResearch TopicGastrointestinal microbiome in neuromyelitis opticaTypeClinicalStatusCompleteTimeline2012 - 2015Researcher(s)Scott Zamvil, MD, PhDUniversity of California, San FranciscoResearch TopicGeneration, characterization and application of AQP4 knockout ratTypeScientificStatusCurrentTimeline2015 - 2016Researcher(s)Alan Verkman, MD, PhDUniversity of California, San FranciscoResearch TopicModels to study NMO disease mechanisms and new therapiesTypeScientificStatusCurrentTimeline2014 - 2016Researcher(s)Alan Verkman, MD, PhDUniversity of California, San FranciscoResearch TopicNMO: New therapies, models and pathogenesis mechanismsTypeScientificStatusCompleteTimeline2012 - 2014Researcher(s)Alan Verkman, MD, PhDUniversity of California, San FranciscoResearch TopicNovel NMO therapeutics: development and animal efficacy studiesTypeScientificStatusCurrentTimeline2016 - 2018Researcher(s)Alan Verkman, MD, PhDUniversity of California, San FranciscoResearch TopicPharmacological upregulation of CD59 in NMOTypeScientificStatusCompleteTimeline2017 - 2018Researcher(s)Alan Verkman, MD, PhDUniversity of California, San FranciscoResearch TopicProduction of human aquaporin 4 (hAQP4)TypeScientificStatusCurrentTimeline2017 - 2019Researcher(s)Robert Stroud, PhDUniversity of California, San FranciscoResearch TopicQuantitative analysis of AQP4 binding by NMO patient seraTypeScientificStatusCompleteTimeline2010 - 2011Researcher(s)Alan Verkman, MD, PhDUniversity of California, San FranciscoResearch TopicRole of AQP4 autoantibody in Neuromyelitis OpticaTypeScientificStatusCompleteTimeline2009 - 2012Researcher(s)Alan Verkman, MD, PhDUniversity of California, San FranciscoResearch TopicSecond generation rat modelsTypeScientificStatusCompleteTimeline2013 - 2014Researcher(s)Alan Verkman, MD, PhDUniversity of California, San FranciscoResearch TopicSecond-generation aquaporumabs and NMO superantibodies for NMO research and therapyTypeScientificStatusCompleteTimeline2012 - 2014Researcher(s)Jeffrey Bennett, MD, PhDUniversity of Colorado, DenverAlan Verkman, MD, PhDUniversity of California, San FranciscoResearch TopicSmall-molecule blocker therapy for NMOTypeScientificStatusCompleteTimeline2010 - 2011Researcher(s)Alan Verkman, MD, PhDUniversity of California, San FranciscoResearch TopicT cell recognition of aquaporin-4 in neuromyelitis opticaTypeScientificStatusCompleteTimeline2008 - 2012Researcher(s)Scott Zamvil, MD, PhDUniversity of California, San Francisco
-
University of Colorado, DenverBackResearch TopicAQP4 autoantibodies and disease pathogenesis in Neuromyelitis OpticaTypeScientificStatusCompleteTimeline2012 - 2014Researcher(s)Jeffrey Bennett, MD, PhDUniversity of Colorado, DenverResearch TopicAQP4-specific immunotherapy in Neuromyelitis OpticaTypeScientificStatusCompleteTimeline2010 - 2012Researcher(s)Jeffrey Bennett, MD, PhDUniversity of Colorado, DenverResearch TopicMonitoring humoral immunity and complement injury in Neuromyelitis OpticaTypeScientificStatusCurrentTimeline2014 - 2016Researcher(s)Jeffrey Bennett, MD, PhDUniversity of Colorado, DenverResearch TopicProduction of AQP4-specific rAbTypeScientificStatusCurrentTimeline2017 - 2018Researcher(s)Jeffrey Bennett, MD, PhDUniversity of Colorado, DenverResearch TopicSecond-generation aquaporumabs and NMO superantibodies for NMO research and therapyTypeScientificStatusCompleteTimeline2012 - 2014Researcher(s)Jeffrey Bennett, MD, PhDUniversity of Colorado, DenverAlan Verkman, MD, PhDUniversity of California, San Francisco
-
University of UtahBackResearch TopicMaintain a Functional Infrastructure for an NMO Patient RegistryTypeScientificStatusCurrentTimeline2018 - 2019Researcher(s)Lawrence Cook, PhDUniversity of UtahResearch TopicNMO Data Coordinating CenterTypeClinicalStatusCurrentTimeline2013 - 2016Researcher(s)Lawrence Cook, PhDUniversity of UtahJohn Rose, MDUniversity of UtahResearch TopicXNAT Imaging RepositoryTypeScientificStatusCurrentTimeline2015 - 2018Researcher(s)Lawrence Cook, PhDUniversity of Utah
-
UT SouthwesternBackResearch TopicNeuromyelitis Optica Clinical ConsortiumTypeClinicalStatusCompleteTimeline2010 - 2011Researcher(s)Michael Levy, MD, PhDJohns HopkinsDean Wingerchuk, MDMayo ClinicBenjamin Greenberg, MDUT SouthwesternResearch TopicNMO Clinical StudyTypeClinicalStatusCurrentTimeline2015 - 2017Researcher(s)Benjamin Greenberg, MDUT Southwestern
-
Yale UniversityBackResearch TopicB cell tolerance defects in NMOTypeScientificStatusCurrentTimeline2015 - 2016Researcher(s)Kevin O’Connor, PhDYale UniversityResearch TopicExploring immune response to vaccine antigens in NMOSD and autoimmunityTypeScientificStatusCurrentTimeline2017 - 2019Researcher(s)Kevin O’Connor, PhDYale University